- Conditions
- High Risk Pregnancy, Bone Marrow
- Interventions
- Arts Intervention
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 7,258
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiometabolic Risk Factors, Diabetes, High Blood Pressure, Obesity, Nutrition Security
- Interventions
- Food is Medicine
- Other
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COPD
- Interventions
- myAirvo3, Pulse oximeter
- Device
- Lead sponsor
- Temple University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 642 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
- Conditions
- HPV Vaccination
- Interventions
- multi-channel communication campaign to promote HPV vaccination
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 15 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Lafayette, Alabama
- Conditions
- Sarcoma
- Interventions
- radiation therapy following surgery
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1983 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
- Interventions
- doxepin hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 120
- States / cities
- Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 476
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
- Conditions
- Bladder Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Interventions
- 3D conformal radiation therapy
- Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- L-alanosine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Alcohol Dependence, Nicotine Dependence
- Interventions
- Low-Dose Topiramate, Placebo, High-Dose Topiramate
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 4
- States / cities
- La Jolla, California • Houston, Texas • Charlottesville, Virginia + 1 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Drug · Radiation
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 85 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Hypertension
- Interventions
- Cardene® I.V.
- Drug
- Lead sponsor
- Facet Biotech
- Industry
- Eligibility
- 2 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Miami, Florida
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Procedure · Drug · Other + 2 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Preeclampsia
- Interventions
- Pravastatin, Placebo
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 145
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- OLA group: Olanzapine, DEX group: Dexamethasone
- Drug
- Lead sponsor
- The Guthrie Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Sayre, Pennsylvania
- Conditions
- Spinocerebellar Degenerations
- Interventions
- high-dose intravenous immunoglobulin (IVIG)
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- Up to 10 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more
- Conditions
- Renal Insufficiency
- Interventions
- Tirofiban
- Drug
- Lead sponsor
- Medicure
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- DeLand, Florida
- Conditions
- Multiple Myeloma (MM)
- Interventions
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Myocardial Fibrosis
- Interventions
- Elucirem (Gadopiclenol)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Community Mental Health Services
- Interventions
- Navigation
- Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- Up to 14 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hyperlipidemia
- Interventions
- Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more
- Conditions
- NODULOCYSTIC ACNE
- Interventions
- Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets
- Drug
- Lead sponsor
- Elorac, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 22 more